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Clinical Trials 
1. History of Clinical Trials 
 
The evaluation of a medical treatment or 
therapeutic procedure has a very long history 
dating back thousands of years1 but it was not 
until the middle of the 20th century that the 
clinical trial as we know it today was first 
developed. Earlier trials, such as trial of 
treatments for scurvy conducted by James 
Lind,2 were flawed in one vital respect, they 
failed to include a robust system of 
randomisation. It is widely acknowledged that 
the first properly conducted randomised trial 
was an evaluation of streptomycin in 
pulmonary tuberculosis conducted by the 
British Medical Research Council.3 The trial 
was different from trials that had gone before 
because of the concealment of allocation 
before randomisation. Knowledge of the 
randomisation schedule before enrolment 
could lead to bias which would seriously 
compromise the trial and invalidate the 
results4, see Section 5. 
 
A total of only 107 patients were randomised 
in the streptomycin trial, but this was sufficient 
to demonstrate a significant benefit in 
mortality and radiological improvement at six 
months. In addition to the concealment of the 
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allocation there were other features of this trial 
that are worthy of note. The assessment of the 
chest radiographs was performed by a 
radiologist who was blind to the allocated 
treatment as were the laboratory technicians 
performing the bacteriological assessments. Of 
particular note was the five year follow-up 
which demonstrated that the early beneficial 
effects were not sustained as a consequence of 
the emergence of streptomycin resistance in 
the treated arm, Table 1, 3 illustrating the 
importance of long term follow-up.  
 
Table 1: Mortality at 6-months and 5-years in 
the Streptomycin trial  
  
 6-month results3 5-year results5 
Strepto
mycin 
Bed 
rest 
Strepto
mycin 
Bed 
rest 
N % N % N % N % 
Mort
ality 
4 7% 1
4 
27
% 
3
2 
58
% 
3
5 
67
% 
N 
asses
sed 
5
5 
100
% 
5
2 
10
0% 
5
5 
100
% 
5
2 
10
0% 
  
Reflecting on his involvement in the 
streptomycin trial many years later, Sir John 
Crofton commented that  “For many of those 
of us who had been involved in the MRC 
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streptomycin trial, randomised trials became a 
way of life, and provided much of the evidence 
upon which rational treatment policies came to 
be based.” 6 The streptomycin trial became the 
model on which the assessment of subsequent 
new drugs and regimens for tuberculosis were 
evaluated, a model that spread to many other 
areas of medicine and has become the gold 
standard whereby new treatments are expected 
to be assessed. However, the presence of 
randomisation is not sufficient in itself if there 
are flaws in the design or conduct of the 
study,7 see Box 1. As a result of the historical 
importance of tuberculosis in clinical trials and 
the many challenges posed by the natural 
history and prolonged treatment required for 
tuberculosis, examples from tuberculosis trials 
are used to describe the concepts in this 
chapter. 
 
2. The importance of RCTs 
 
The limitations of observational studies 
Observational studies might appear to be an 
attractive alternative to randomised trials since 
they may be more representative of the patient 
population, are much simpler and require 
fewer resources to conduct,  and can be usually 
be completed  in a shorter space of time than is 
required for a randomised trial. They do, 
  
 
RUNNING HEAD1  
 
5 
 
however, have serious limitations and need to 
be interpreted with considerable caution 
because of potential biases.8  An example of 
this is a case study of a randomised trial and an 
observational study in which the same two 
anti-retroviral regimens were compared using 
death as the endpoint.9 Unexpected results in 
the observational study were probably due to 
patients with poorer prognosis being given one 
regimen in preference to the other.9  Guyatt et 
al summarise potential limitations  of 
nonrandomised studies noting common sources 
of bias include failure to develop appropriate 
eligibility criteria, differences in measurement 
of exposure and outcome, failure to adequately 
control for confounding and incomplete 
follow-up7, Box 1. The difference between the 
limitations in randomised trials and 
observational studies is that the former can be 
avoided by careful planning whereas it is often 
not possible to avoid those in observational 
studies.  
  
Box 1: Possible limitations in randomised trials 
and observational studies (based on Guyatt et 
al. 7) 
 
Randomised trials  Observational 
studies 
1 Lack of allocation concealment 1 Failure to apply  
appropriate 
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eligibility criteria 
2 Lack of blinding 2 Flawed 
measurement of 
exposure and 
outcome 
3 Incomplete accounting of 
patients and outcomes 
3 Failure to 
adequately control 
confounding 
4 Selective outcome reporting 
bias 
4 Incomplete 
follow-up 
5 Other including early stopping, 
unvalidated outcomes 
 
  
A criticism often made of randomised trials is 
that they do not reflect real life10. An 
advantage of observational data, provided it is 
systematically collected, is the potential 
completeness of coverage, since patients who 
do not satisfy the eligibility requirements or 
those who are unwilling to participate in a 
randomised trial are not excluded. Valuable 
information on outcomes of different 
interventions may be obtained from medical 
records of high quality but the limitation of 
lack of randomisation will always mean 
potential differences in the patient populations 
cannot be fully discounted or allowed for.  
 
Pragmatic and explanatory trials 
A trial is described as pragmatic if the 
objective is to evaluate the intervention under 
conditions that are close to usual care and as 
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explanatory if the objective is to evaluate the 
intervention under optimal conditions, testing 
the principle of whether an intervention 
actually works. This distinction is more a 
continuum than a dichotomy with trials having 
features that could be considered more or less 
pragmatic or explanatory.11 Very loose 
eligibility criteria for entry into the study, 
including all patients who would require 
treatment irrespective of other comorbidities, 
for example, would make a trial more 
pragmatic whereas regular follow-up visits 
outside of usual care would make a trial more 
explanatory. Both types of trials are of value – 
explanatory trials provide proof of concept that 
an intervention is efficacious and can be 
delivered safely while pragmatic trials show 
what is likely to happen when the intervention 
is implemented in practice. 
 
The initial trials of short course chemotherapy 
for tuberculosis conducted by the British 
Medical Research Council in East Africa were 
more explanatory than pragmatic, conducted 
under strictly controlled conditions; patients 
were hospitalised throughout treatment and 
followed intensively throughout treatment and 
for 24 months of follow-up.12 Subsequently, a 
trial conducted in Algeria under programme 
conditions with patients seen mostly as 
outpatients with limited supervision of their 
  
CHAPTER 1 Clinical Trials 8 
 
treatment gave results consistent with the 
findings of earlier studies13, thus 
strrengthening the evidence base for the 
regimen. 
 
A comparison of results from a controlled trial 
and those from the tuberculosis programme, 
both conducted in Kenya, gave contrasting 
results, higlighting the limitations of highly 
explanatory trials.  Whilst the survey 
confirmed the poor results obtained in the trial 
with a regimen of thiacetazone and isoniazid 
alone, the results of a regimen with an initial 
supplement of streptomycin were substantially 
better in the trial, 96% culture negative at one 
year, compared to only 78% in the programme. 
The difference in outcomes was attributed to 
poorer adherence to treatment in the 
continuation phase of treatment under routine 
conditions.14 
 
 
3. Types, phases and designs 
of trials 
 
There are traditionally considered to be four 
separate phases of clinical trials which are 
described in Box 2.  
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Box 2. Phases of clinical trials 
Phase 
I 
The first time a drug has been given 
to a human, participants are healthy 
volunteers. The objective is to assess 
safety and achieve some indication of 
a maximum tolerated dose of the 
drug. 
Phase 
II 
 
Participants are patients with the 
disease being studied. The objective 
is to achieve a preliminary evaluation 
of efficacy and further explore safety 
over a longer period of time in a 
larger group of patients. Phase II is 
often split into phase IIA with more 
focus on dose selection and safety 
and phase IIB with more focus on 
efficacy, often on an intermediate 
endpoint.  
 
 
Phase 
III 
The pivotal phase III trial involves 
treatment with the new drug for the 
intended duration with sufficient 
numbers of patients to allow for an 
unequivocal demonstration of 
efficacy on a definitive patient-
relevant outcome.  
 
 
Phase The objective of the phase IV trial is 
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IV to collect longer-term safety data in 
much larger numbers of patients than 
were enrolled in previous trials; often 
embedded into routine practice post-
licensing. 
 
In TB drug development, a short (14-day) early 
bactericidal activity (EBA) study to evaluate 
safety and compare doses in 12-15 patients per 
arm would be a phase IIA trial, whereas a 
study evaluating decline in TB bacilli over 8-
12 weeks in 60-100 patients per arm would be 
a phase IIB trial.  A phase III trial would 
evaluate treatment failure and relapse over 18-
24 months of follow-up as the primary 
endpoint with hundreds of patients per arm, 
with usual standard of care are the comparator.  
 
Classifying trials into phases can be overly 
restrictive. The development pathway may not 
always the same as an intervention may move 
from a small early-phase trial directly into a 
large confirmatory trial if the results are 
promising. 
 
Superiority and Non-inferiority 
 
The commonest type of type of late-phase (II-
III) trial has a superiority design where the 
objective of the trial is to evaluate whether the 
intervention has superior efficacy to a standard 
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treatment control. However, non-inferiority 
designs are increasingly used, where the 
objective is to evaluate whether the 
intervention has efficacy that is as good as that 
of the control. To demonstrate non-inferiority, 
it is necessary to show that the intervention is 
no more inferior than a pre-specified amount. 
This difference is called the margin of non-
inferiority. A non-inferiority trial is only 
appropriate when the intervention has 
additional benefits over the control such as 
being less toxic, less costly or of shorter 
duration. The use of non-inferiority trials for 
interventions with no additional benefit has led 
to some over-reactive criticism, with some 
describing any non-inferiority trial as unethical 
15-20. The current treatment of Multi-Drug 
Resistant TB (MDR-TB) is an area where non-
inferiority trials are appropriate. MDR-TB is 
currently treated with combinations of toxic 
drugs daily for 20-24 months, severely limiting 
a patient’s ability to return to work and other 
daily activities. Trials are evaluating 
substantially shorter, less toxic regimens that 
would result in major patient benefit even if 
efficacy is only at least as good as that of the 
current treatment21. 
 
Phase III trials for new treatments for drug 
sensitive TB commonly have a non-inferiority 
design since the standard 6-month regimen has 
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excellent efficacy in clinical trials that does not 
always translate well into clinical practice due 
to the long duration of treatment. A shorter 2 
month regimen, for example, that had efficacy 
not much worse than the standard of care 
would likely translate into much improved 
outcomes in practice due to improved 
adherence. The remainder of this chapter 
focuses on superiority trials. 
 
Adaptive trial designs 
 
In a traditional fixed-sample trial, analysis 
occurs only at the end of the trial once all 
patients have completed follow-up and all data 
accrued. An alternative to this approach is an 
adaptive design where there are one or more 
interim analyses during the course of the study 
and these interim results used to adapt the 
study design. Possible adaptations include 
changing the sample size, stopping a trial early 
for overwhelming efficacy or lack of benefit, 
or dropping arms in a multi-arm study. 
Importantly, such adaptation should never be 
used to attempt to salvage a failing trial and 
procedures for adaptation must be pre-
specified in the study protocol before the study 
begins (see Trial Monitoring section below). 
Consideration must be given of the impact of 
any interim analyses on the overall type I and 
type II errors (see section 4 Power and Sample 
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Size). Where there are several promising new 
interventions but limited resources, a 
particularly attractive design is the Multi-Arm 
Multi-Stage (MAMS) design where multiple 
arms are compared simultaneously with a 
single control. The MAMS design allows for 
multiple interim analyses to facilitate the early 
termination of poorly performing arms in order 
that resources can be focused on the more 
promising arms. This methodology was 
developed in cancer trials22,23 but is being 
adapted for use in trials of new TB drugs24,25. 
 
Other trial designs 
In most randomised controlled trials, 
individual participants are randomly allocated 
to treatment arms. An alternative is a cluster 
randomised trial which evaluate an 
intervention that is applied to a ‘cluster’ of 
individual participants, at the community- or 
health system-level, where clusters rather than 
individual participants are randomised to 
receive one of the interventions26.  An 
intervention such as improved methods for 
tuberculosis case-finding, for example, would 
be better suited to a cluster-randomised trial. 
 
Other trial designs that are not covered here 
include step wedge cluster randomised trials, 
factorial trials and sequential multiple 
assignment randomized trials (SMARTs). 
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4. Power and sample size 
 
The sample size of a trial is the minimum 
number of participants required to be enrolled 
in a clinical trial to achieve the trial objective. 
It is unethical to enrol either insufficient 
patients to achieve the trial objective or more 
patients than are necessary.. Sample size 
calculations are driven by minimising the 
probability of Type I and Type II errors. In a 
superiority trial, the Type I error is the 
probability of demonstrating a difference when 
no difference exists while the Type II error is 
the probability or failing to show a difference 
when there actually is a real difference 
between interventions (see figure).  
 
It is common to maintain the type I error rate 
low at 5%, but usually acceptable to allow a 
type II error rate of 10-20%. The Power of a 
trial is the probability that an effective 
intervention will be demonstrated to be so and 
is calculated by subtracting the type II error 
rate from 100%; a power of 90% corresponds 
to a type II error rate of 10%.  
 
 
Figure: Type I and II errors 
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Type I error. Wrongly declaring a 
difference when one doesn’t exist.  
 
Type II error. Not declaring a difference when 
one does exist. 
 
When a trial includes multiple interventions, 
multiple primary endpoints or when multiple 
analyses have been conducted (such as in an 
adaptive design), there is an increased chance 
of falsely finding a statistically significant 
difference if a conventional significance level 
of 5% is used for each comparison. In this 
context, it is appropriate to either adjust the 
individual significances levels to maintain the 
overall type I error rate at an acceptable rate 
(such as 5%) or take multiple testing into 
account when interpreting the results27,28. 
 
Having decided on values for the Type I error 
rate and power, the targeted effect size or 
difference between treatments is another key 
driver for the sample size. A trial designed 
with adequate power to detect a small effect 
size will be larger than one designed to detect a 
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large effect size. It is good practice to link the 
targeted effect size to the minimum clinically 
important difference (MCID) so that the trial is 
designed to detect effect sizes at least as large 
as the MCID and would only miss effects not 
considered clinically important. This highlights 
the distinction between statistical significance 
when there is evidence that a difference, 
however small, does exist and clinical 
significance when the difference is considered 
large enough for the intervention to change 
practice.  
 
An important factor that influences the sample 
size is the expected outcome in the control 
arm. If this turns out to be very different to 
what was assumed when the trial was 
designed, the trial may turn out to be 
underpowered. It is therefore recommended to 
use a conservative estimate from previous 
trials, if available.  
 
It is usually necessary to enrol more patients 
than is required for the analysis to account for 
loss to follow-up. It is important to make 
realistic estimates about the expected rate of 
loss to follow-up when designing a trial; these 
need to be kept as low as possible when 
conducting the trial since the true outcome of 
such patients remains unknown.  Differential 
losses to follow-up may indicate that one 
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treatment regimen is less acceptable or more 
toxic than another and results in bias in 
interpretation of the data. Other sources of bias 
are described in the next section. 
5. Methods for avoidance of 
bias 
The estimated effect of an intervention from a 
clinical trial is said to be biased if there is 
systematic error such that it does not reflect the 
true intended effect of the intervention.  There 
are a number of sources of bias and 
corresponding measures to avoid bias. 
 
Randomisation is the most critical method in 
an RCT to prevent bias as, if properly 
implemented, it ensures that any known and 
unknown factors that might affect outcomes 
are balanced between arms with any imbalance 
occurring by chance. Proper implementation 
involves adequate allocation concealment, 
ensuring that neither the patient nor the 
investigator is aware of which arm a patient 
will be allocated to before consent has been 
obtained for enrolment in the trial. This avoids 
selection bias where patients are selected for 
particular arms such as, for example, sicker 
participants being allocated to the control arm 
by an investigator concerned about a novel 
treatment. 
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Blinding (sometimes also called masking) is a 
well established method in clinical trials to 
avoid bias by keeping secret which treatment a 
patient is on. The strongest form of blinding is 
known as double-blind when neither the 
patient, clinicians, investigators nor any other 
individuals carrying out assessments (such as 
laboratory technicians) know what arm the 
patient has been allocated to until completion 
of the trial. The purpose of blinding is to 
ensure that every aspect of patient management 
and data collection is unaffected by the 
knowledge of which arm a patient has been 
allocated to. Blinding is particularly important 
when the primary endpoint has a subjective 
element such as a patient reported quality of 
life measure but less important when the 
primary endpoint is objective such as all-cause 
mortality.  
 
Blinding is achieved in a treatment trial by 
giving patients on the control arm identical 
inactive tablets (placebo) at the same 
frequency as on the intervention arm. A 
double-blind trial can be very difficult; it is 
challenging to produce an inactive perfectly-
matched placebo for the TB drug rifampicin, 
for example, which turns a patient’s urine and 
bodily fluids an orange colour. Blinding will 
also substantially increase the complexity and 
  
 
RUNNING HEAD1  
 
19 
 
cost of a clinical trial due to the manufacture of 
matching placebo and central packing facilities 
separate from the trial sites. 
 
Even when it is not feasible or desirable to 
blind patients and clinicians (in which case the 
trial is sometimes designated as being open 
label), it is still important to limit knowledge 
of patient allocation for endpoint assessors 
wherever possible and also ensure that only the 
Independent Data Monitoring Committee 
(IDMC, see Section 6) are aware of aggregated 
data by treatment arm. If the primary endpoint 
involves some clinical judgement (identifying 
AIDS-defining illness, for example) an 
endpoint review committee of experts 
independent to the trial could be convened to 
review the data blinded to treatment allocation 
and classify outcomes.  
 
To ensure that no trial procedures change 
during the course of a trial as a response to 
accruing data (particularly important in an 
open label study) key aspects of the trial such 
as trial objectives, primary endpoint, primary 
methods of analysis should be clearly pre-
specified in the protocol and remain unchanged 
once the first patient has been enrolled. The 
statistical analysis plan which provides details 
of the analysis of the primary and secondary 
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endpoints should also be finalised and signed 
off early in the trial.  
 
Publication bias occurs where there is selective 
reporting of trial outcomes to favour the 
intervention or where whole trials with 
unfavourable outcomes are not reported. For 
this reason, it is now expected by most clinical 
trials funders that a trial is registered, namely 
key details are lodged with publically available 
registries (such as ClinicalTrials.gov or 
International Standard Randomised Controlled 
Trial Number Register, ISRCTN) before the 
study starts. In this way, individuals 
conducting systematic reviews or those 
wanting to find out about a particular disease 
or intervention can search registries to find a 
more comprehensive picture of which trials are 
being or have been conducted.  
 
6. Trial Monitoring 
Unless the quality of the data obtained in a 
randomised controlled clinical trial can be 
relied upon, the results of the trial will be of no 
value. If a trial is being conducted according to 
the principles of the International Conference 
on Harmonisation Good Clinical Practice (ICH 
GCP) regulations29, regular monitoring is 
essential. This can be performed in a number 
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of ways and to varying degrees. A GCP 
requirement is that monitors should be 
appropriately trained and should have the 
scientific and/or clinical knowledge needed to 
monitor a trial adequately.29 In the past, 
monitoring was often only done by monitors 
visiting study sites and reviewing data and 
documentation with little regard to a strategy 
of prioritisation within the process. More 
recently, alternative approaches have been 
advocated30 and these include central statistical 
monitoring 31,32 and the use of a risk 
assessment conducted at the start of a trial to 
identify the most appropriate monitoring 
strategies for the trial and for individual sites30. 
A risk assessment should be reviewed on an 
annual periodic basis throughout a clinical trial 
and the monitoring techniques employed 
considered and updated accordingly. 
Monitoring, whether done on site, centrally or 
both, may highlight the need for additional site 
staff training or changes in trial procedures. 
 
Safety monitoring and expedited reporting 
In addition to the determination of efficacy, an 
essential assessment in clinical trials is the 
safety of the interventions being studied.  It is 
recommended that patients should be asked at 
each trial visit about any disability or 
incapacity or adverse events that have occurred 
as well as hospitalisations amd consultations 
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with other medical practitioners . ICH GCP 
regulations set out the responsibilities for the 
notification of adverse events by investigators 
to sponsors.29 These include the reporting of 
any defined serious adverse events (SAEs) 
within an agreed time frame with particular 
expedited reporting requirements by sponsor to 
regulatory authorities for Suspected 
Unexpected Serious Adverse Reactions 
(SUSARs).  
  
The Independent Data Monitoring 
Committee and Trial Steering Committee 
All trials of medicinal products are expected to 
have an Independent Data Monitoring 
Committee (IDMC), its purpose is to protect 
the safety of the trial participants, the 
credibility of the study and the validity of the 
study results.33 The membership, which is 
often no more than three to five people, should 
be totally independent of the trial and include 
clinical trial, statistical and relevant clinical 
expertise. The IDMC is expected to meet 
regularly, commonly every 6 months during 
the trial to review study progress and 
unblinded data on safety and efficacy. At the 
conclusion of each meeting the IDMC will 
make its recommendations to an executive 
decision making body such as the Trial 
Steering Committee (TSC) as to whether the 
trial should continue as designed or whether 
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modifications should be made. These could 
include early termination of one or more study 
arms on account of safety concerns or proof 
beyond reasonable doubt of differences in 
efficacy between one of the study arms and its 
comparator. 
 
The TSC is a committee which provides expert 
oversight of the trial, monitoring progress on a 
regular basis and receiving the 
recommendations of the IDMC.   The majority 
of members of the TSC, including the chair, 
should be independent of the trial although 
additional observers may be present at TSC 
meetings. In addition to deciding on the 
appropriate response following receipt of the 
IDMC recommendations, the TSC may be 
required to attend to issues of concern 
regarding trial conduct. These include poor 
recruitment or poor data quality, the approval 
of proposed protocol amendments or new trial 
sub-studies, the approval of requests for early 
release of data or external applications for the 
use of stored samples, and the approval of 
study reports or presentations. 
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7. Ethical approval and 
informed consent 
Before commencing a trial, approval needs to 
be obtained from an independent research 
ethics committee to protect the rights and 
interests of the trial participants. This approval 
will usually be from more than one committee 
and will typically include a central ethics 
committee, often based in the same country as 
the trial sponsor, and ethics committees in each 
participating country or site. In the United 
Kingdom, for example, only the central 
committee approval is required for all sites.  
Any amendments to be made to the study 
protocol need to be approved by the ethics 
committee(s) before they can be introduced. 
 
Informed consent must be obtained from all 
persons being considered for enrolment to the 
trial before any investigations are performed; 
this includes investigations to assess the 
eligibility for admission to the trial. Key 
information that needs to be conveyed to the 
patient includes the rationale for the study, 
potential risks and benefits, the trial treatments, 
the randomisation process, the follow-up 
schedule and right of participants to withdraw 
at any time. Before enrolling in the study a 
patient consent form needs to be signed. If the 
person cannot read patient information 
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documentation, an independent witness should 
be present during the consent process. 
 
8. Dissemination and impact 
 
It is important that the results of a clinical trial 
are published in peer-reviewed journals and 
disseminated in scientific conferences but this 
is insufficient as this will only reach the 
scientific community. There is an ethical 
obligation that the results of the trial should 
also be shared with the trial participants and 
the communities where the trial was conducted 
including the investigators and other site staff. 
This can sometimes take the form of a 
community meeting as a celebration of trial 
completion.  
 
The impact of a clinical trial is often measured 
by how high profile the journal that the paper 
is published in is and how many times it is 
subsequently cited in other scientific 
publications. This is only one component of 
impact which can also be measured by, among 
other things, the extent to which national and 
international treatment guidelines are changed 
as a result of the trial, whether practitioners are 
actually using the new intervention to treat 
their patients or resulting advocacy activities 
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by patient and community groups. Funding 
agencies, such as the British Medical Research 
Council, now require that groups conducting 
clinical trials include steps to increase impact 
beyond just publication of the results in a peer-
reviewed journal. 
 
To have impact broader than just to the 
scientific community, additional methods of 
dissemination can therefore include press 
releases, videos posted on YouTube, policy 
briefing documents for governments and health 
ministries and direct contact with organisations 
such as the World Health Organisation that 
produce treatment guidelines. Having reports 
in journals published as open access, such that 
the publication is freely available to everyone 
without subscription, will also increase 
dissemination.  
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